NCT03329950 2024-03-28A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced MalignanciesCelldex TherapeuticsPhase 1 Completed132 enrolled
NCT03602079 2023-08-03Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 GeneKlus Pharma Inc.Phase 1/2 Completed49 enrolled
NCT00743262 2023-07-25Short-term Clinical Feasibility of the New Provox Vega 22.5 Voice ProsthesisAtos Medical ABPhase 1/2 Completed15 enrolled 7 charts
NCT03254927 2023-04-03A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell CarcinomaCelldex TherapeuticsPhase 2 Terminated30 enrolled 17 charts
NCT04129320 2022-02-08Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and NeckMacroGenicsPhase 2/3 Withdrawn
NCT01045057 2021-06-11Clinical Feasibility of New Tracheoesophageal Puncture SetAtos Medical ABPhase NA Completed27 enrolled 9 charts
NCT00661570 2017-03-10Long-term Clinical Feasibility of the New Indwelling Provox Vega 20 Voice ProsthesisAtos Medical ABPhase NA Terminated26 enrolled 8 charts
NCT00080028 2007-05-08Motexafin Gadolinium With Chemotherapy and Radiation Therapy for the Treatment of Advanced Head and Neck CancerPharmacyclics LLC.Phase 1 Terminated18 enrolled